2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne; fellow at Victorian Cancer Agency; and chair of the ANZUP Cancer Trials Group Translational, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).
The post-hoc analyses, which were presented virtually during the 2020 ESMO Congress, evaluated whether baseline prostate-specific antigen (PSA) influenced outcomes in patients with mHSPC who had prior exposure to androgen deprivation therapy (ADT), explains Azad.
Notably, over 90% of patients enrolled on the ARCHES study had received prior ADT, Azad says. Moreover, 18% had received prior docetaxel.
As such, patients’ baseline PSA levels upon enrollment were different than their baseline levels at diagnosis, Azad explains.
Patients were stratified by baseline PSA levels of 0.2 µg/L or less (n = 134), greater than 0.2 µg/L but less than 4 µg/L (n = 372), and greater than 4 µg/L (n = 541).
Notably, results of the analyses showed a clinical benefit in terms of radiographic progression-free survival and other key secondary end points with the addition of enzalutamide (Xtandi) plus ADT versus placebo plus ADT, irrespective of baseline PSA levels prior to starting enzalutamide, Azad concludes.